MeiraGTx (MGTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $9.89, +5.10% vs the prior close of $9.41.
- Volume 836.40K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MGTX jumps 5.1% to $9.89. Closed at $9.89, +5.10% vs the prior close of $9.41. Day range $9.38–$9.93, opened at $9.42.
MGTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — MGTX jumps 5.1% to $9.89
- Closed at $9.89, +5.10% vs the prior close of $9.41. Day range $9.38–$9.93, opened at $9.42.
- Volume was 836.40K shares, 1.0x its 50-day average of 856.25K.
- Price is -21.4% vs its 50-day average ($12.58) and -3.0% vs its 200-day average ($10.20).
- 52-week range $6.62–$15.35; today's close sits at 37% of that range, 35.6% below the 52-week high.
Oct 14, 2026 — MGTX slides 5.3% to $9.41, a 3-month low, 3 down days in a row
- Closed at $9.41, -5.33% vs the prior close of $9.94. Day range $9.36–$10.01, opened at $9.82.
- Volume was 1.10M shares, 1.3x its 50-day average of 845.63K.
- Price is -25.5% vs its 50-day average ($12.63) and -7.6% vs its 200-day average ($10.19).
- 52-week range $6.62–$15.35; today's close sits at 32% of that range, 38.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — MGTX slides 4.2% to $9.94, a 3-month low
- Closed at $9.94, -4.24% vs the prior close of $10.38. Day range $9.86–$10.40, opened at $10.26.
- Volume was 1.12M shares, 1.3x its 50-day average of 832.98K.
- Price is -21.7% vs its 50-day average ($12.69) and -2.4% vs its 200-day average ($10.18).
- 52-week range $6.62–$15.35; today's close sits at 38% of that range, 35.2% below the 52-week high.
Oct 12, 2026 — MGTX dips 2.9% to $10.38, a 3-month low
- Closed at $10.38, -2.90% vs the prior close of $10.69. Day range $10.32–$10.76, opened at $10.69.
- Volume was 506.50K shares, 0.6x its 50-day average of 833.19K.
- Price is -18.4% vs its 50-day average ($12.73) and +2.0% vs its 200-day average ($10.17).
- 52-week range $6.62–$15.35; today's close sits at 43% of that range, 32.4% below the 52-week high.
Oct 9, 2026 — MGTX rises 1.8% to $10.69
- Closed at $10.69, +1.81% vs the prior close of $10.50. Day range $10.48–$10.99, opened at $10.52.
- Volume was 523.40K shares, 0.6x its 50-day average of 831.88K.
- Price is -16.2% vs its 50-day average ($12.76) and +5.2% vs its 200-day average ($10.16).
- 52-week range $6.62–$15.35; today's close sits at 47% of that range, 30.4% below the 52-week high.
Oct 8, 2026 — MGTX dips 3.0% to $10.50, a 3-month low
- Closed at $10.50, -2.96% vs the prior close of $10.82. Day range $10.35–$10.72, opened at $10.70.
- Volume was 830.40K shares, 1.0x its 50-day average of 825.67K.
- Price is -17.8% vs its 50-day average ($12.78) and +3.5% vs its 200-day average ($10.15).
- 52-week range $6.62–$15.35; today's close sits at 44% of that range, 31.6% below the 52-week high.
Oct 7, 2026 — MGTX rises 2.1% to $10.82 on 2.9x normal volume
- Closed at $10.82, +2.08% vs the prior close of $10.60. Day range $10.32–$11.01, opened at $10.50.
- Volume was 2.31M shares, 2.9x its 50-day average of 788.69K — unusually heavy trading.
- Price is -15.5% vs its 50-day average ($12.80) and +6.7% vs its 200-day average ($10.14).
- 52-week range $6.62–$15.35; today's close sits at 48% of that range, 29.5% below the 52-week high.
Oct 6, 2026 — MGTX dips 2.9% to $10.60, a 3-month low
- Closed at $10.60, -2.93% vs the prior close of $10.92. Day range $10.52–$10.95, opened at $10.93.
- Volume was 944.40K shares, 1.2x its 50-day average of 781.52K.
- Price is -17.3% vs its 50-day average ($12.82) and +4.7% vs its 200-day average ($10.12).
- 52-week range $6.62–$15.35; today's close sits at 46% of that range, 30.9% below the 52-week high.
Oct 5, 2026 — MGTX rises 1.2% to $10.92
- Closed at $10.92, +1.20% vs the prior close of $10.79. Day range $10.59–$11.03, opened at $10.77.
- Volume was 941.60K shares, 1.2x its 50-day average of 772.63K.
- Price is -15.1% vs its 50-day average ($12.86) and +8.0% vs its 200-day average ($10.11).
- 52-week range $6.62–$15.35; today's close sits at 49% of that range, 28.9% below the 52-week high.
Oct 2, 2026 — MGTX rises 1.2% to $10.79
- Closed at $10.79, +1.22% vs the prior close of $10.66. Day range $10.65–$11.00, opened at $10.75.
- Volume was 820.00K shares, 1.1x its 50-day average of 763.82K.
- Price is -16.2% vs its 50-day average ($12.87) and +6.8% vs its 200-day average ($10.10).
- 52-week range $6.62–$15.35; today's close sits at 48% of that range, 29.7% below the 52-week high.
MGTX latest news & SEC filings
Every SEC filing by or about MGTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Naylor Stuart sold 27,659 shares at $10.64 (≈$294.29K) on Oct 6, 2026; now holds 613,187
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 24, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Forbes Alexandria sold 62,000 shares at $13.86 (≈$859.32K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $321.43M (prior year $3.69M) (+8608.6% vs Jun 30, 2025)
- Net income: $160.72M (prior year -$38.80M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $1.71 (prior year -$0.48) (swung to profit vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade MGTX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 26, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.83% (largest 6.0%).
- Liquidity: about 1.12M shares (≈$11.12M) trade per day on average.
- 52-week position: $9.89 vs a range of $6.62–$15.35 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 10 sales; latest: Alexandria Forbes sold 62,000 shares on Aug 18, 2026.
- Latest filings: 8-K Sep 23, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 96.04M shares outstanding (Aug 11, 2026), +19.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
MGTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 9.42 | 9.93 | 9.38 | 9.89 | 836.40K |
| Oct 14, 2026 | 9.82 | 10.01 | 9.36 | 9.41 | 1.10M |
| Oct 13, 2026 | 10.26 | 10.40 | 9.86 | 9.94 | 1.12M |
| Oct 12, 2026 | 10.69 | 10.76 | 10.32 | 10.38 | 506.50K |
| Oct 9, 2026 | 10.52 | 10.99 | 10.48 | 10.69 | 523.40K |
| Oct 8, 2026 | 10.70 | 10.72 | 10.35 | 10.50 | 830.40K |
| Oct 7, 2026 | 10.50 | 11.01 | 10.32 | 10.82 | 2.31M |
| Oct 6, 2026 | 10.93 | 10.95 | 10.52 | 10.60 | 944.40K |
| Oct 5, 2026 | 10.77 | 11.03 | 10.59 | 10.92 | 941.60K |
| Oct 2, 2026 | 10.75 | 11.00 | 10.65 | 10.79 | 820.00K |
| Oct 1, 2026 | 11.36 | 11.36 | 10.53 | 10.66 | 1.07M |
| Sep 30, 2026 | 11.19 | 11.60 | 10.97 | 11.00 | 1.42M |
| Sep 29, 2026 | 11.02 | 11.17 | 10.87 | 11.13 | 875.90K |
| Sep 28, 2026 | 10.79 | 11.27 | 10.59 | 11.11 | 930.00K |
| Sep 25, 2026 | 10.90 | 11.28 | 10.68 | 10.91 | 1.56M |
| Sep 24, 2026 | 11.42 | 11.56 | 11.00 | 11.05 | 1.61M |
| Sep 23, 2026 | 12.26 | 12.50 | 11.46 | 11.75 | 1.42M |
| Sep 22, 2026 | 13.16 | 13.24 | 12.18 | 12.35 | 1.44M |
| Sep 21, 2026 | 13.47 | 13.47 | 12.80 | 13.08 | 1.29M |
| Sep 18, 2026 | 12.92 | 13.34 | 12.92 | 13.25 | 941.20K |
About MeiraGTx
MeiraGTx (MGTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW YORK, NY. Fiscal year ends December 31. SEC CIK 1735438.
MGTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Joseph Edelman | Director | Jun 15, 2026 |
| Alexandria Forbes | PRESIDENT & CEO | Aug 18, 2026 |
| Keith R. Harris | Director | Jun 15, 2026 |
| Ellen Hukkelhoven | Director | Jun 15, 2026 |
| Neil Mendoza | Director | Jun 15, 2026 |
| Advisors Llc Perceptive | Director | Jun 15, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | Jun 15, 2026 |
| Alan Sebulsky | Director | Sep 24, 2026 |
| Thomas E Shenk | Director | Jun 15, 2026 |
| Nicole Seligman | Director | Jun 15, 2026 |
| Debra Yu | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | May 14, 2026 |
| Alexandria Forbes | PRESIDENT & CEO | Aug 18, 2026 |
| Richard Giroux | CFO & COO | Jul 21, 2026 |
| Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 7, 2026 |
| Robert J Wollin | GENERAL COUNSEL AND SECRETARY | Jun 29, 2026 |
| Robert K Zeldin | CHIEF MEDICAL OFFICER | Jun 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Alexandria Forbes | Sale | 62,000 | $13.86 |
| Jul 21, 2026 | Richard Giroux | Sale | 56,000 | $12.51 |
| Jul 7, 2026 | Stuart Naylor | Sale | 25,112 | $14.90 |
| Jul 7, 2026 | Stuart Naylor | Sale | 2,547 | $13.86 |
| May 19, 2026 | Alexandria Forbes | Sale | 62,000 | $9.17 |
| Apr 21, 2026 | Richard Giroux | Sale | 56,000 | $10.22 |
| Apr 7, 2026 | Stuart Naylor | Sale | 27,661 | $9.36 |
| Mar 24, 2026 | Alexandria Forbes | Sale | 62,000 | $7.41 |
| Oct 21, 2025 | Richard Giroux | Sale | 24,000 | $8.87 |
| Oct 7, 2025 | Alexandria Forbes | Sale | 47,500 | $8.39 |
MGTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-114.20M | -1.42 | $-46.36M |
| Dec 31, 2024 | — | $-147.79M | -2.12 | $-104.50M |
| Dec 31, 2023 | — | $-84.03M | -1.49 | $-105.36M |
| Dec 31, 2022 | $15.92M | $-129.62M | -2.87 | $-73.10M |
| Dec 31, 2021 | $37.70M | $-79.56M | -1.80 | $-10.53M |
Latest balance sheet: total assets $396.45M, total liabilities $180.67M, cash $143.17M (as of Jun 30, 2026).
MGTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $12.67 |
| May 14, 2026 | 8-K Item 2.02 (results) | $9.95 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $7.53 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $8.26 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $8.33 |
| May 13, 2025 | 8-K Item 2.02 (results) | $5.15 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $8.25 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $7.04 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on MGTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.